Literature DB >> 17079438

Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective.

Martin Götte1, George W Yip.   

Abstract

Glycosaminoglycans are major constituents of the cancer cell surface and the tumor stroma. The heparan sulfate degrading enzyme heparanase, hyaluronan, and its receptor CD44 are up-regulated in breast cancer, generating a microenvironment that promotes tumor progression and metastasis. Recent experimental and clinical evidence shows that heparanase, hyaluronan, and CD44 regulate cancer cell proliferation, migration, and invasion, as well as tumor-associated angiogenesis and are correlated with patient survival. These findings suggest that they may be used as prognostic factors and targets for breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079438     DOI: 10.1158/0008-5472.CAN-06-1464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  127 in total

1.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Unique SNP in CD44 intron 1 and its role in breast cancer development.

Authors:  Juhua Zhou; Prakash S Nagarkatti; Yin Zhong; Kim Creek; Jiajia Zhang; Mitzi Nagarkatti
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

3.  A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?

Authors:  Amanda Weyers; Bo Yang; Dae Sung Yoon; Jong-Hwan Park; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  OMICS       Date:  2012-03

4.  Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis.

Authors:  Juhua Zhou; Prakash Nagarkatti; Yin Zhong; Mitzi Nagarkatti
Journal:  J Neuroimmunol       Date:  2010-06       Impact factor: 3.478

5.  In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver.

Authors:  Allal Ouhtit; Zakaria Y Abd Elmageed; Mohamed E Abdraboh; Tong F Lioe; Madhwa H G Raj
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

6.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01

Review 7.  Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.

Authors:  Suzanne Eccles; Lenaic Paon; Jonathan Sleeman
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

8.  The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.

Authors:  Shradha S Khurana; Terrence E Riehl; Benjamin D Moore; Matteo Fassan; Massimo Rugge; Judith Romero-Gallo; Jennifer Noto; Richard M Peek; William F Stenson; Jason C Mills
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

9.  Modulation of hyaluronan production by CD44 positive glioma cells.

Authors:  Marzenna Wiranowska; Sharron Ladd; Lynn C Moscinski; Bobbye Hill; Ed Haller; Katalin Mikecz; Anna Plaas
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

10.  Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion.

Authors:  Melissa L T Teoh; Matthew P Fitzgerald; Larry W Oberley; Frederick E Domann
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.